Please upgrade your browser.
In the webcast series, Renal Cell Carcinoma, expert faculty will provide evidence-based recommendations that synthesize current advances and data into clinical practices that improve the screening, diagnosis, treatment, and overall care of this patient population.
A meeting agenda, including the complete list of distinguished faculty for the symposium is available online. A special discount of $100 is available to those who register online by August 31, 2012.
Public health and patientsâ groups around the world have been protesting against free trade agreements that the United States and European Union are negotiating with developing countries, because of their effects on raising the prices of medicines including for life-threatening diseases.
The literature was reviewed for the actions and clinical effects of IL2 on subsets of T cells. The influence of IL2 on clinical efficacy was also sought.
Purpose: To assess the efficacy of contrast-enhanced ultrasonography (CEUS) with Sonovue in the evaluation of therapeutic response to radiofrequency ablation (RFA) of renal cell carcinoma (RCC).
Biosceptre's technology is based on the discovery of what potentially could be the world's first truly universal cancer marker/target â a non-functional cellular receptor (nf-P2X7) that is found on cancer cells but is never present on healthy cells.
Seattle Genetics, Inc. (SGEN) today announced the initiation of a phase Ib clinical trial evaluating SGN-75 in combination with everolimus (AfinitorÂ®) for patients with advanced metastatic renal cell carcinoma (RCC).
A cancer drug that isn't passing muster in clinical trials may still be the answer for some patients, a new study says.
A marker for diagnosis, prognosis and treatment
Join your friends from the Kidney Cancer Association for SU2C from Hollywood, September 7, 2012
|Powered by NeonCRM|